Bayer Proposes $7.25 Billion Roundup Cancer Settlement

Agrochemical giant Bayer announced a proposed $7.25 billion settlement on Tuesday with attorneys representing thousands of cancer patients in the United States, aiming to resolve lawsuits claiming the company failed to warn users that its widely used weedkiller Roundup could cause cancer.

The agreement, filed in St. Louis Circuit Court in Missouri, targets claims from individuals who developed non-Hodgkin's lymphoma after exposure to Roundup. The product's active ingredient, glyphosate, has been at the center of the litigation, with plaintiffs alleging that Bayer and its subsidiary Monsanto, acquired by the German-based company in 2018, knew of potential health risks but did not include adequate warnings on labels. Bayer maintains that scientific evidence does not support a causal link between glyphosate and cancer, pointing to approvals from regulatory bodies worldwide.

This development arrives amid ongoing legal challenges, including a case before the U.S. Supreme Court. The high court is set to hear arguments on Bayer's position that the Environmental Protection Agency's approval of Roundup without a cancer warning should preempt similar claims in state courts. The proposed...